SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Miscellaneous >

OncBioMune Pharmaceuticals Inc. (OBMP)

OBMP RSS Feed
Add OBMP Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog
Search This Board: 
Last Post: 10/16/2017 6:35:09 PM - Followers: 42 - Board type: Free - Posts Today: 0

Image result for oncbiomune pharmaceuticals inc

OncBioMune Pharmaceuticals Inc.
11441 Industriplex Blvd.
Suite 190
Baton Rouge, LA 70809

Corporate Office: 1-225-227-2384
Fax: 1-225-227-2957

corporate@oncbiomune.com

http://oncbiomune.com/


 

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event. Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program. Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane).  


 





LEADERSHIP

 

Image result for Dr. Jonathan Head

Dr. Jonathan Head, Ph.D.

  

CHIEF EXECUTIVE OFFICER, CHAIRMAN

Dr. Head has been instrumental in the development of our new chemotherapy and immunotherapy programs. Dr. Head and Dr. Elliott are the co-developers and patent holders of one of the first patented autologous breast cancer vaccines in the United States.  His major goal is to implement translational research – the movement of laboratory-developed technologies into the clinical setting.  This is the taking of new therapies from cell culture to an accepted therapy for cancer patients.

As a tumor cell biologist, Dr. Head’s specialties include:

Cell culture research
Animal research
Human clinical research
Innovative chemotherapies
Immunotherapy/cancer vaccines
Oncogene and antisense research
Tumor markers

Dr. Head is an Adjunct Associate Professor of Biochemistry at Tulane University School of Medicine, an Adjunct Professor of Physical and Biological Sciences at Delta State University and an Adjunct Associate Professor at Louisiana State University School of Veterinary Medicine.   He is an active member of the American Association for Cancer Research and the American Society of Clinical Oncology. Although patients rarely meet Dr. Head, the new treatments we offer are the result of his and Dr. Elliott’s work.

 
 



Image result for Dr. Robert Elliott


Dr. Robert Elliott, M.D., Ph.D.

 
 

CHIEF MEDICAL OFFICER, DIRECTOR

Dr. Robert Elliott is the driving force behind our The Elliott-Elliott-Head Breast Cancer Research and Treatment Center.  Colleagues often remark that his energy seems boundless. Indeed, it often is.

In 1973, when the Center was founded, Dr. Elliott’s dream was to create the finest center for total breast care. With that step behind us, the dream continues.  Dr. Elliott continues doing research to discover new treatments and drug therapies, and has implemented a team approach to bring total breast care to the patients.

Dr. Elliott sees patients from all over Louisiana, the Southeast and across the United States. He collaborates on research projects with other scientists around the world. Dr. Elliott has spoken to medical audiences in the United States and Europe and has authored many papers and abstracts. He has also published a book, Breast Cancer, Anger at the Enemy, which deals with the lack of total breast care available for women. He shares his own frustration and heartaches of caring for dying cancer patients as they struggle for survival, and finally sends a message of hope as he and his research team search for a cure for breast cancer.

Trained as a general surgeon, Dr. Elliott feels that breast care should be a specialty of itself, with patients being able to receive the highest quality of care from one physician who reads their mammograms, examines them, performs their surgery and administers their therapies.

To advance this concept and to share his experience with other physicians like himself who specialize in breast care, Dr. Elliott founded the American Mastology Association. He currently serves as President of this society. In spite of a busy calendar of meetings and research, Dr. Elliott’s first love is his patients. He devotes the majority of his time to the Center and to helping women overcome breast disease.

 
 

Image result for Dr. Andrew Kucharchuk


Andrew Kucharchuk

 
 

CHIEF FINANCIAL OFFICER, PRESIDENT, DIRECTOR

Andrew “Al” Kucharchuk is a graduate of Louisiana State and Tulane Universities Freeman School of Business, where he earned an MBA with a Finance Concentration. He currently serves as the Company’s Chief Financial Officer and oversees the business and administrative processes.  In addition to these duties, Al also directs business development efforts including the expansion of operations to accommodate increased research and clinical development. Al has assisted Dr. Head in the administration of the three contracts that have lead to the clinical studies for the Company’s lead product, ProscaVax™.

Mr. Kucharchuk is a member of Kappa Alpha Order fraternity. He lives in Baton Rouge with his wife Jessica and their sons Henry and Davis.

 
 



Image result for Charles Rice obmp

Charles L. Rice, Jr.

 
 

DIRECTOR

Mr. Rice is the President and Chief Executive Officer of Entergy New Orleans, Inc., an $800 million a year electric and gas utility and subsidiary of NYSE-listed Entergy Corporation.  After his first legal private practice position in Louisiana with Jones, Walker, Waechter, Poitevent, Carrere & Denegre, L.L.P, Rice joined Entergy in the legal department in 2000, serving as senior counsel in the Entergy Services, Inc. litigation group and then as manager of labor relations litigation support in human resources.

Rice was recruited into New Orleans city government in 2002 as the city attorney and later took the critical role of chief administrative officer for the City of New Orleans, where he managed 6,000 employees and the city’s $600 million budget. In 2005, the law firm of Barrasso, Usdin, Kupperman, Freeman & Sarver, L.L.C. recruited him back to private practice, where he was named partner.

Returning to Entergy in 2009, Rice served as director of utility strategy where he was responsible for coordinating regulatory, legislative, and communications efforts to develop and execute strategies that advanced commercial objectives for the company’s regulated service areas. He then served as director of regulatory affairs for Entergy New Orleans.

Rice holds a bachelor’s degree in business administration from Howard University, a juris doctorate from Loyola University’s School of Law and master’s degree in business administration from Tulane University. After graduating from Howard University, he was commissioned as a second lieutenant in the United States Army and served as a military intelligence officer with the 101st Airborne Division (Air Assault) at Fort Campbell, KY. While in the Army, he earned the Airborne Badge, Air Assault badge and was awarded the Army Commendation and the Army Achievement medals.

He is a member of the Alabama and Louisiana State Bar Associations, the American Bar Association, the New Orleans Bar Association, and the National Bar Association.

 
 
 

Image result for Daniel Hoverman obmp

Daniel Hoverman

 
 
 

DIRECTOR

Daniel Hoverman is a Director at NYSE-listed Houlihan Lokey, a leading global investment bank, where he is a senior member of the firm’s Corporate Finance Group. Mr. Hoverman is also actively involved with Houlihan Lokey’s efforts in equity capital markets.

Mr. Hoverman has extensive mergers and acquisitions advisory and financing experience, having completed over $100 billion of transactions for both private and public companies across multiple industries and geographies. Before joining Houlihan Lokey, he was a Director with Credit Suisse in Hong Kong as a member of the office of the General Counsel, and was responsible for oversight and management of investment banking transactions. Prior to Credit Suisse, he was a Director with UBS Investment Bank in New York as a member of the firm’s Equity Capital Markets Group and Equity Corporate Finance Team, where he was responsible for origination, oversight and management of securities offerings. He began his career with Kirkland & Ellis LLP as a corporate attorney focusing on capital markets and mergers and acquisition transactions.

Mr. Hoverman received a B.A. from Yale University, where he graduated cum laude with distinction in history and was a Robert C. Bates Fellow and New Prize recipient, and received a J.D. and M.B.A. from Columbia University, where he was a James Kent Scholar and a John C. Olin Fellow. Mr. Hoverman holds Series 7, 24, 63 and 79 licenses and the designation of Chartered Financial Analyst, and is an inactive member of the New York Bar.

 

 
 
Image result for Daniel Hoverman obmp

Dr. J. Jacques Carter

 
 
 

SCIENTIFIC ADVISORY BOARD MEMBER

Dr. Carter currently serves as a physician at the Beth Israel Deaconess Medical Center in Boston, MA and is an assistant professor at Harvard Medical School. From 2005 to 2014, he also served as the Medical Director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.

Dr. Carter completed his residency training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, followed by a graduate program at the Harvard School of Public Health, where he received his MPH degree. He then completed a clinical fellowship in Primary Care Medicine at the Massachusetts General Hospital.

Dr. Carter has held a number of clinical and administrative positions, including Medical Directorships of several local and national health care organizations. A former director of one of the major clerkships, he now serves as a teacher/advisor/mentor for students at Harvard Medical School and the Harvard School of Public Health. Dr. Carter has been active in a number of civic and community organizations, including past president of the board of Family Service of Greater Boston and past chair of the Brookline Advisory Council on Public Health. He regularly gives talks on medical and health related issues to community groups and students throughout greater Boston. He also lectures nationally and internationally on medical and public health topics. Dr. Carter serves as a medical consultant and resource for members of the media. He is a past President of the Harvard School of Public Health Alumni Association and a current director of the Harvard Alumni Association. Dr. Carter is a founding member of the Georgetown University African American Advisory Board. He is the recipient of the 2010 Harvard Medical School/Harvard School of Dental Medicine Community Service Lifetime Achievement Award. His bio has been included in “Who’s Who in the East, “Who’s Who in Medicine and Healthcare”, Who’s Who in Science and Engineering, and “Who’s Who in America”.
 



 
 

OBMP Daily Chart





 

OBMP Weekly Chart



 



Image result for Things to know

 

All OBMP SEC Filings can be found here:   http://oncbiomune.com/sec-filings/

 

All OBMP Stock Information can be found here:   http://oncbiomune.com/stock-information/

 

All OBMP Events and Presentations can be found here:    http://oncbiomune.com/events-and-presentations/








Image result for news signs


 

OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

 

BATON ROUGE, LA—(June 21, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to report that that the Mexican Institute of Industrial Property has issued patent No. 343266, titled “Composition and Method for Treating Cancer,” protecting the intellectual rights of OncBioMune’s ProscaVax throughout Mexico until January 8, 2032.

ProscaVax is a clinical-stage protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune’s intellectual property portfolio protecting ProscaVax and other technologies consists of 16 patents and patents pending spanning approximately 50 countries worldwide.

“This patent is particularly important given the Mexican markets are integral to our business model. We expect to announce the official commencement of our Phase 2/3 trial of ProscaVax for late-stage prostate cancer in Mexico any day now, so the timing of the new patent couldn’t be any better,” commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. “An aging population and widespread adoption of screening for prostate specific antigen have Mexico facing a prostate cancer dilemma with little alternatives free of unpleasant side effects. We are optimistic that ProscaVax can provide a safe and effective solution to the nation’s problem for years to come.”


OncBioMune Awarded Patent for ProscaVax in Japan

 

BATON ROUGE, LA–(June 20, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, today announces that patent No. 6118730 has been granted by the Japan Patent Office.

The patent, titled, “Composition and Method for Treating Cancer,” protects the intellectual rights of OncBioMune’s ProscaVax in Japan until January 8, 2032.

ProscaVax is a clinical-stage protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune’s intellectual property portfolio protecting ProscaVax and other technologies consists of 16 patents spanning approximately 50 countries worldwide.

 

OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico

 

Jun 19, 2017 (Marketwired via COMTEX) -- MEXICO CITY, MEXICO--(Marketwired - June 19, 2017) - OncBioMune México, S.A. De C.V., (otcqb:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and owner of vaccine technology and commercialization of a portfolio of products internationally announced the completion of the acquisition of the sanitary registration and intellectual property rights of Norepinefrine (Norepinephrine) for the Mexican market from Teva Pharmaceuticals Mexico, S.A. de C.V. (Teva), the Mexican subsidiary of Teva Pharmaceuticals, Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day.

Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure. OncBioMune intends to immediately initiate distribution of Norepinefrine throughout its sales channels across Mexico.

The Norepinefrine registration can also be used in other Central and Latin American countries. OncBioMune is conducting its due diligence with plans to selectively launch the drug in other markets in the future.

"The acquisition of Norepinefrine adds the first big generic medicine to our Mexican product bag and we anticipate it will immediately gain traction with physicians," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "We are feeling very confident in our future, given Bekunis® had a record sales month in May, the approval of our male fertility product Andfrt® two weeks ago and now closing the acquisition of Norepinefrine. Our team is already mobilizing to bring Andfrt® and Norepinefrine to market and making sure the supply chain can meet expected demand."

 

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

 

More OBMP news can be found here:  http://oncbiomune.com/news/

 





Image result for happenings




Image result for obmp pipeline


 

ProscaVax – A Novel Prostate Cancer Vaccine

 

The Company has developed a therapeutic cancer vaccine for  prostate cancer patients using similar techniques developed for breast cancer patients. It is tested and laboratory proven and could become the standard of care for prostate cancer treatment. The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.

The Company has data from a phase 1/2 clinical trial of their therapeutic prostate cancer vaccine. Patients with prostate cancer confirmed by biopsy and with an elevated PSA received the vaccine. We enrolled 12 patients in this study. All patients received their initial course of six vaccinations containing prostate specific antigen and biological adjuvant. Serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination. Two-thirds of the prostate cancer patients’  PSAs decreased after vaccination. During the trial  the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy), and have additionally received three further vaccinations alternated with low dose IL-2 for the 6 months following the initial vaccinations. The Company developed the protocol for the vaccination of prostate cancer patients using techniques developed for vaccination of breast cancer patients.  We are currently in a Phase 1 clinical trial at UCSD Medical School under an IND from the FDA with funding from the US Navy Cancer Vaccine Program. If proven effective clinically,  it could become the standard of care for prostate cancer.

Information on the current clinical trial of ProscaVax can be found on the clinictrials.gov at https://clinicaltrials.gov/ct2/show/NCT02058680?term=oncbiomune&rank=1.

 

OvcaVax

Breast cancers and other epithelial malignancies are antigenic and elicit lymphocyte responses in the autologous host, and patients that express good host immunity to their tumor have better survival. Adequate host immunity is an independent prognostic indicator and those with poor immunity have  shorter disease free intervals and shorter overall survival. The Company’s novel approach defines the tumor specific immune status of patients both pre and post immunotherapy that uses autologous tumor antigens to immunize patients. We have the ability to discriminate patients who are immunologically unreactive to tumor antigens and may be generally lymphocyte depressed from those who are tumor antigen reactive and lymphocyte competent.  Thus those patients who are unreactive and in need of immunostimulation qualify for vaccination with specific tumor antigen .

We developed our vaccine in 1993 and then immediately began vaccinating patients with depressed immunity. We obtained the first patent on a breast cancer vaccine in the U.S.A. in 1994, and were the first to use the cytokines GM-CSF and IL-2 as biological adjuvants. Appropriate patients are vaccinated in the adjuvant setting and patients with advanced disease are treated with a combined chemo-immunotherapy protocol. Some of these patients have had dramatic responses.

The Company is presently devoting much research to the tumor stroma and microenvironment for a better understanding of tumor escape mechanisms. This will allow us the ability to better attack the tumor with specific adaptive immunotherapy. This work is in progress and early results are producing exciting results.

 

 

 


 


 

 

SureTrader
Interactive Brokers Advertisement
OBMP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#2006  Sticky Note Accumulating for the phase 2 kick off at BooDog 09/20/17 06:25:52 AM
#2091   JR Honestly I've been looking yet haven't seen anything. iInvest734 10/16/17 06:35:09 PM
#2090   BooDog: Did anything come out of the conference in J.R. Ewing 10/16/17 05:58:35 PM
#2089   The whole biotech sector is beginning its biannual selloff Apophis 10/16/17 01:27:54 PM
#2088   LC, you sound disgruntled.........as if someone took away southerngent1 10/15/17 03:54:26 PM
#2087   If anyone is interested. I've found this to iInvest734 10/12/17 12:43:22 PM
#2086   Do you think the penny stock boiler room learningcurve2020 10/12/17 10:54:01 AM
#2085   One word - "Leadership" learningcurve2020 10/12/17 10:52:19 AM
#2084   It would be nice for this to work Apophis 10/11/17 08:01:23 PM
#2083   Will keep an eye on the FDA site BooDog 10/11/17 06:25:39 PM
#2082   I there anything online from these phase 2 studies? Apophis 10/11/17 11:09:08 AM
#2080   Accumulating in 2 accounts. IRA and regular equity. BooDog 10/10/17 02:07:12 PM
#2079   None of that is your business, of course. learningcurve2020 10/10/17 08:34:48 AM
#2078   Apophis, Seriously? A complaint with the SEC? southerngent1 10/09/17 06:03:09 PM
#2077   LC, Thinking about selling out with a down view? southerngent1 10/09/17 06:00:35 PM
#2076   Anticipate P2 is approved by FDA anytime from Maple tree 10/09/17 02:24:55 PM
#2075   Early financial models have the company expecting to BooDog 10/06/17 06:41:05 AM
#2074   I might file a complaint with the SEC Apophis 10/05/17 06:28:25 PM
#2073   Like I said, they seem to telegraph everything. learningcurve2020 10/05/17 06:23:23 PM
#2072   They should have not released projected earnings out Apophis 10/05/17 02:49:01 PM
#2071   ...$139,125 was due Oct 1, 2017. learningcurve2020 10/05/17 01:17:27 PM
#2070   Correct. No future presentations or anything. learningcurve2020 10/05/17 01:13:17 PM
#2069   And what about the $344k loan bearing interest learningcurve2020 10/05/17 01:06:56 PM
#2068   future / projected is not a concrete revenue stream Apophis 10/05/17 10:59:33 AM
#2067   Are you implying they have no revenue? southerngent1 10/05/17 12:05:46 AM
#2066   I hope they do not do a reverse Apophis 10/04/17 10:18:52 PM
#2065   Tells me to buy all I can up BooDog 10/04/17 03:06:41 PM
#2064   And what does your dd tell you about learningcurve2020 10/04/17 02:50:21 PM
#2063   They keep selling shares at garbage prices and learningcurve2020 10/04/17 02:47:35 PM
#2062   I'll try and stay under the filing requirement BooDog 10/04/17 10:44:07 AM
#2061   Market are forward looking by years usually so learningcurve2020 10/04/17 10:31:29 AM
#2060   I believe this quarter at Beth. Yes, BooDog 10/04/17 07:18:26 AM
#2059   Immunotherapy is next generation stuff. Excited to be iInvest734 10/03/17 11:42:27 PM
#2058   BooDoog thank You. I bought a JamieE 10/03/17 10:07:31 AM
#2057   Fast may be an option once phase BooDog 10/03/17 09:36:54 AM
#2056   I thought the program was on "fast track" JamieE 10/03/17 09:16:57 AM
#2055   Trial at Beth is 2 years. Maybe on BooDog 09/30/17 11:31:02 AM
#2054   Sometime, reverse split to list in Nasdaq is Maple tree 09/30/17 10:51:28 AM
#2053   Years in the making before any splits. Revenue BooDog 09/29/17 04:56:26 PM
#2052   Are the sneaking in massive dilution for another learningcurve2020 09/29/17 03:38:01 PM
#2051   That's what they should've done over at PPHM learningcurve2020 09/29/17 03:32:32 PM
#2050   Revenue doesn't get you cash unless it's profitable or... learningcurve2020 09/29/17 03:31:30 PM
#2049   We should all pool our money and buy Apophis 09/29/17 12:58:57 PM
#2048   Anything that helps minimize dilution is a plus. Walking Dread 09/29/17 12:26:29 PM
#2047   Excellent. Revenue streams to help pay for BooDog 09/29/17 12:23:58 PM
#2046   Not a lot of money expected to be Apophis 09/29/17 12:22:09 PM
#2045   OncBioMune CMO Producing First Batch of Tretinoin for Walking Dread 09/29/17 11:29:58 AM
#2044   Do you know what would cure this dreadful learningcurve2020 09/29/17 10:15:42 AM
#2043   Scottrade shows: gmwestrup 09/29/17 09:11:55 AM
#2042   YOU ARE CORRECT, VERY UNDERVALUED HERE, EASILY .25 Apophis 09/29/17 09:10:34 AM
#2041   The OS has increased significantly over the past dtdude 09/29/17 09:00:57 AM
PostSubject